相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Adebrelimab or placebo plus carboplatin and etoposide as first-line treatment for extensive-stage small-cell lung cancer (CAPSTONE-1): a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial
Jie Wang et al.
LANCET ONCOLOGY (2022)
Serplulimab, a novel anti-PD-1 antibody, plus chemotherapy versus chemotherapy alone as first-line treatment for extensive-stage small-cell lung cancer: An international randomized phase 3 study.
Ying Cheng et al.
JOURNAL OF CLINICAL ONCOLOGY (2022)
Patterns of transcription factor programs and immune pathway activation define four major subtypes of SCLC with distinct therapeutic vulnerabilities
Carl M. Gay et al.
CANCER CELL (2021)
Durvalumab, with or without tremelimumab, plus platinum-etoposide versus platinum-etoposide alone in first-line treatment of extensive-stage small-cell lung cancer (CASPIAN): updated results from a randomised, controlled, open-label, phase 3 trial
Jonathan W. Goldman et al.
LANCET ONCOLOGY (2021)
First-line nivolumab plus ipilimumab combined with two cycles of chemotherapy in patients with non-small-cell lung cancer (CheckMate 9LA): an international, randomised, open-label, phase 3 trial
Luis Paz-Ares et al.
LANCET ONCOLOGY (2021)
Identification of a prognostic immune-related signature for small cell lung cancer
Qi Xie et al.
CANCER MEDICINE (2021)
Use of Immunotherapy With Programmed Cell Death 1 vs Programmed Cell Death Ligand 1 Inhibitors in Patients With Cancer A Systematic Review and Meta-analysis
Jianchun Duan et al.
JAMA ONCOLOGY (2020)
Randomized phase II clinical trial of cisplatin/carboplatin and etoposide (CE) alone or in combination with nivolumab as frontline therapy for extensive-stage small cell lung cancer (ES-SCLC): ECOG-ACRIN EA5161.
Ticiana Leal et al.
JOURNAL OF CLINICAL ONCOLOGY (2020)
Pembrolizumab or Placebo Plus Etoposide and Platinum as First-Line Therapy for Extensive-Stage Small-Cell Lung Cancer: Randomized, Double-Blind, Phase III KEYNOTE-604 Study
Charles M. Rudin et al.
JOURNAL OF CLINICAL ONCOLOGY (2020)
IMpower133: Characterisation of long-term survivors treated first-line with chemotherapy ± atezolizumab in extensive-stage small cell lung cancer
S. V. Liu et al.
ANNALS OF ONCOLOGY (2020)
Third-Line Nivolumab Monotherapy in Recurrent SCLC: CheckMate 032
Neal Ready et al.
JOURNAL OF THORACIC ONCOLOGY (2019)
Durvalumab plus platinum-etoposide versus platinum-etoposide in first-line treatment of extensive-stage small-cell lung cancer (CASPIAN): a randomised, controlled, open-label, phase 3 trial
Luis Paz-Ares et al.
LANCET (2019)
The effect of age on referral to an oncologist and receipt of chemotherapy among small cell lung cancer patients in Ontario, Canada
Jordan Doherty et al.
JOURNAL OF GERIATRIC ONCOLOGY (2019)
Pembrolizumab plus Chemotherapy in Metastatic Non-Small-Cell Lung Cancer
L. Gandhi et al.
NEW ENGLAND JOURNAL OF MEDICINE (2018)
Defining the Most Appropriate Primary End Point in Phase 2 Trials of Immune Checkpoint Inhibitors for Advanced Solid Cancers A Systematic Review and Meta-analysis
Georgia Ritchie et al.
JAMA ONCOLOGY (2018)
Can duration of response be used as a surrogate endpoint for overall survival in advanced non-small cell lung cancer?
Boris M. Pfeiffer et al.
JOURNAL OF CLINICAL ONCOLOGY (2018)
First-Line Atezolizumab plus Chemotherapy in Extensive-Stage Small-Cell Lung Cancer
L. Horn et al.
NEW ENGLAND JOURNAL OF MEDICINE (2018)
Pembrolizumab plus Chemotherapy for Squamous Non-Small-Cell Lung Cancer
L. Paz-Ares et al.
NEW ENGLAND JOURNAL OF MEDICINE (2018)
Current standards for clinical management of small cell lung cancer
Anna F. Farago et al.
TRANSLATIONAL LUNG CANCER RESEARCH (2018)
Nivolumab plus ipilimumab as first-line treatment for advanced non-small-cell lung cancer (CheckMate 012): results of an open-label, phase 1, multicohort study
Matthew D. Hellmann et al.
LANCET ONCOLOGY (2017)
The Humanistic Burden of Small Cell Lung Cancer (SCLC): A Systematic Review of Health-Related Quality of Life (HRQoL) Literature
Bryan M. Bennett et al.
FRONTIERS IN PHARMACOLOGY (2017)
Immuno-oncology Trial Endpoints: Capturing Clinically Meaningful Activity
Valsamo Anagnostou et al.
CLINICAL CANCER RESEARCH (2017)
Phase III Randomized Trial of Ipilimumab Plus Etoposide and Platinum Versus Placebo Plus Etoposide and Platinum in Extensive-Stage Small-Cell Lung Cancer
Martin Reck et al.
JOURNAL OF CLINICAL ONCOLOGY (2016)
Nivolumab in Previously Untreated Melanoma without BRAF Mutation
Caroline Robert et al.
NEW ENGLAND JOURNAL OF MEDICINE (2015)
Pembrolizumab versus Ipilimumab in Advanced Melanoma
Caroline Robert et al.
NEW ENGLAND JOURNAL OF MEDICINE (2015)
Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma
J. Larkin et al.
NEW ENGLAND JOURNAL OF MEDICINE (2015)
Neoantigens in cancer immunotherapy
Ton N. Schumacher et al.
SCIENCE (2015)
Genetic Basis for Clinical Response to CTLA-4 Blockade in Melanoma
Alexandra Snyder et al.
NEW ENGLAND JOURNAL OF MEDICINE (2014)
Nivolumab (anti-PD-1; BMS-936558, ONO-4538) and ipilimumab in first-line NSCLC: Interim phase I results.
Scott Joseph Antonia et al.
JOURNAL OF CLINICAL ONCOLOGY (2014)
Ipilimumab in combination with paclitaxel and carboplatin as first-line therapy in extensive-disease-small-cell lung cancer: results from a randomized, double-blind, multicenter phase 2 trial
M. Reck et al.
ANNALS OF ONCOLOGY (2013)
Carboplatin- or Cisplatin-Based Chemotherapy in First-Line Treatment of Small-Cell Lung Cancer: The COCIS Meta-Analysis of Individual Patient Data
Antonio Rossi et al.
JOURNAL OF CLINICAL ONCOLOGY (2012)
Integrative genome analyses identify key somatic driver mutations of small-cell lung cancer
Martin Peifer et al.
NATURE GENETICS (2012)
Safety, Activity, and Immune Correlates of Anti-PD-1 Antibody in Cancer
Suzanne L. Topalian et al.
NEW ENGLAND JOURNAL OF MEDICINE (2012)
A small-cell lung cancer genome with complex signatures of tobacco exposure
Erin D. Pleasance et al.
NATURE (2010)
Improved Survival with Ipilimumab in Patients with Metastatic Melanoma
F. Stephen Hodi et al.
NEW ENGLAND JOURNAL OF MEDICINE (2010)
Carboplatin plus paclitaxel in extensive small cell lung cancer: a multicentre phase 2 study
C Gridelli et al.
BRITISH JOURNAL OF CANCER (2001)
分享论文
